All In MedTech

Device Trial Radar · NCT03218423

Longitudinal Performance of Epi proColon

Performance of Epi proColon in Repeated Testing in the Intended Use Population (PERT)

Last checked: Nov 19, 2026Latest source record: Nov 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

4,500

Planned (sponsor's estimate)

Start

Aug 18, 2017

Primary completion

Aug 2023

Study completion Jan 2024

Sponsor

Lead sponsor
Epigenomics, IncNot on our public-company list
Sponsor type
Industry
First posted
Jul 14, 2017

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 50 years, up to 74 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate longitudinal performance of Epi proColon with respect to test positivity, longitudinal adherence to Epi proColon screening, adherence to follow-up colonoscopy and diagnostic yield, as well as assay failure rates.

Conditions

  • Colorectal Cancer
  • Colorectal Neoplasms

Interventions

  • Epi proColonDevice

    Plasma cell free DNA SEPT9 promoter methylation test for colorectal cancer screening.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The difference in test specificity between initial testing and repeat testing 1 yearTime frame: Through study completion, expected at 60 months
  2. Detection of colorectal cancerTime frame: Through study completion, expected at 60 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Veterans Affairs San Diego Healthcare System

    San Diego, California · Recruiting

  • Beaumont Health System

    Royal Oak, Michigan · Recruiting

  • Rutgers University Hospital

    New Brunswick, New Jersey · Recruiting

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.